Josh Kaufman

Partner

Co-Chair, Capital Markets and Public Company Advisory Practice

US-LatAm Practice Group Regional Co-Leader, Capital Markets

"My clients turn to me as a trusted advisor for their most critical financing and corporate transactions."

New YorkMiami
About

Josh Kaufman is a commercially oriented corporate counselor who advises high-growth businesses on financing pathways, strategic development and transformational transactions. He specializes in cross-border matters, having advised leading innovative companies in Asia, Europe, Latin America and the Middle East. Mr. Kaufman represents US and foreign private issuers and underwriters, primarily in the digital asset, life sciences and technology sectors, in a wide variety of public offerings and private placements. He has advised on more than 200 financing transactions with an aggregate value in excess of US$100 billion. Mr. Kaufman represents clients before the Securities and Exchange Commission (SEC), and advises on corporate governance, general corporate and commercial matters.

Areas of FocusCorporateEquity Capital MarketsHealthcareLife SciencesTechnologyReal Estate Capital Markets
Bar admissionsNew YorkFlorida

EXPERIENCE

  • Counsel to Predictive Oncology in US$344 million of private placements to create a Digital Asset Treasury focused on Aethir Tokens (ATH)
  • Counsel to Injective Foundation in US$100 million private placement into Pineapple Financial Inc. to create a Digital Asset Treasury focused on Injective Tokens (INJ)
  • US counsel to Empresa Distribuidora de Electricidad de Mendoza S.A. (EDEMSA) of US$400 million of Class 6 Notes
  • Counsel to TD Securities, William Blair and Lake Street in a US$86.9 million follow-on equity offering for Butterfly Network
  • US counsel to Danish biotech on US$1 billion equity capital raise through leading global investment banks
  • US counsel to Swedish biopharma on US$1.1 billion friendly cash tender offer from Japanese conglomerate
  • Advised underwriting syndicates in the first dual listings of Danish and Swedish companies in the United States
  • Advised a New York biotech in its US$40 million initial public offering (IPO) and numerous follow-on offerings
  • Advised an underwriting syndicate on a UK pharmaceutical company's US$380 million IPO
  • Advised a national restaurant chain in its US$140 million primary offering and US$75 million at-the-market (ATM) offering
  • Advised the sales agents on a US$1 billion ATM for an agency residential mortgage real estate investment trust (REIT)
  • Advised a UK-listed biotech in its transition to Nasdaq and numerous follow-on offerings
  • Advised on four technology and healthcare IPOs out of Israel aggregating US$1.2 billion
  • Advised a national shopping center REIT on a US$950 million IPO

AWARDS AND RECOGNITIONS

The Legal 500 United States

  • Recommended, Capital Markets: Equity Offerings, (2025)
  • Recommended, Corporate Governance, (2025)
Additional Recognitions
  • Finalist, Daily Business Review Dealmaker of the Year, (2025)
Education
  • J.D., Columbia Law School, 2002
  • M.B.A., Columbia Business School, 2002
  • A.B., Harvard University, 1998

Publications

Media Mentions

  • Mentioned, "Deal Watch: Deals and IPOs Keep Popping, With Private Equity 'Near Full Throttle'," Law.com, October 14, 2025

Prior Experience

Prior to joining DLA Piper, Mr. Kaufman served as partner at one Am Law 100 law firm and prior to that as counsel at another Am Law 100 law firm. He previously worked as an investment banker at Lehman Brothers, focused on corporate financings and leveraged buyouts.

My latest insights

News

DLA Piper advises Corvex on all-stock merger with Movano

12 November 2025

Publication

2026 SEC filing deadlines and financial statement staleness dates

12 November 2025

News

DLA Piper advised Predictive Oncology in US$343.5 million digital asset treasury launch

8 October 2025

View All
CallvCardLinkedInPrint

Connect

Phone

+1 212 335 4640
(Work, New York)
+1 305 423 8500
(Work, Miami)